bremelanotide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R | Highest reported agonist potency within the family |
| Secondary receptor activity | MC1R and MC3R | Lower potency than at MC4R |
| Elimination half-life | About 2 to 3 hours | Measured after subcutaneous administration |
| Plasma protein binding | Approximately 44 percent | Species- and assay-dependent |
| Route of administration | Subcutaneous injection | Reviewed product uses a single-use device |
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
The internal examination evaluates the condition of the nasal septum, the internal and external nasal valves, the turbinates, and the nasal lining, paying special attention to the structure and the form of the nasal dorsum and the tip of the nose. Furthermore, when warranted, specific tests—the mirror test, vasoconstriction examinations, and the Cottle maneuver—are included to the pre-operative evaluation of the prospective rhinoplasty patient. Established by Maurice H. Cottle (1898–1981), the Cottle maneuver is a principal diagnostic technique for detecting an internal nasal-valve disorder; whilst the patient gently inspires, the surgeon laterally pulls the patient's cheek, thereby simulating the widening of the cross-sectional area of the corresponding internal nasal valve. If the maneuver notably facilitates the patient's inspiration, that result is a positive Cottle sign—which generally indicates an airflow-correction to be surgically effected with an installed spreader-graft. Said correction will improve the internal angle of the nasal valve and thus allow unobstructed breathing. Nonetheless, the Cottle maneuver occasionally yields a false-positive Cottle sign, usually observed in the patient affected by alar collapse, and in the patient with a scarred nasal-valve region.
=== Flavin adenine dinucleotide === Interacts with the cofactor or prosthetic group, FAD of flavoproteins and contains a flavin moiety in the form of FAD or FMN (flavin mononucleotide). The domain non-covalently binds oxidized FAD or its reduced form, hydroquinone (FADH2).
=== Romanian Revolution === List of books about the Romanian Revolution List of films about the Romanian Revolution Ilie Verdeț, tried to take over power on 22 Dec 1989, but was pushed aside by I. Iliescu Videograms of a Revolution
=== Critical response === On Rotten Tomatoes, the film has an approval rating of 18% based on 50 reviews, with an average of 3.4/10. The website's critical consensus reads, "An action thriller starring Mads Mikkelsen as the world's most dangerous assassin should be terrifically entertaining, but Polar proves it's possible to ruin anything if you try." On Metacritic, the film has a weighted average score of 19 out of 100, based on reviews from 12 critics, indicating "overwhelming dislike".
Sources: en.wikipedia.org
== Structure-activity relationships == There is a rather large homology in structure between arenobufagin and cardiac glycosides. Cardiac glycosides are natural compounds found in plants which cause inactivation of the sodium potassium pump like arenobufagin. The specific steroidic structure binds to the pump in a way it inhibits the process of pumping potassium into the cell and sodium out of the cell. The exact way of binding to the Na-K-Pump is not yet documented.
=== Mitochondrial Ca2+ uniporter (MCU) === The mitochondrial calcium uniporter (MCU) is a protein complex located in the inner mitochondrial matrix that functions to take up calcium ions (Ca2+) into the matrix from the cytoplasm. The transport of calcium ions is specifically used in cellular function for regulating energy production in the mitochondria, cytosolic calcium signaling, and cell death. The uniporter becomes activated when cytoplasmic levels of calcium rise above 1 uM. The MCU complex comprises 4 parts: the port-forming subunits, regulatory subunits MICU1 and MICU2, and an auxiliary subunit, EMRE. These subunits work together to regulate the uptake of calcium in the mitochondria. Specifically, the EMRE subunit functions for the transport of calcium, and the MICU subunit functions in tightly regulating the activity of MCU to prevent the overload of calcium concentrations in the cytoplasm. Calcium is fundamental for signaling pathways in cells, as well as for cell death pathways. The function of the mitochondrial uniporter is critical for maintaining cellular homeostasis. The MICU1 and MICU2 subunits are a heterodimer connected by a disulfide bridge. When there are high levels of cytoplasmic calcium, the MICU1-MICU2 heterodimer undergoes a conformational change. The heterodimer subunits have cooperative activation, which means Ca2+ binding to one MICU subunit in the heterodimer induces a conformational change on the other MICU subunits. The uptake of calcium is balanced by the sodium-calcium exchanger.
Self was concerned that NAA had not ever designed a fighter, insisting they obtain the drawings and study the wind-tunnel test results for the P-40, before presenting them with detailed design drawings based on the agreed concept. NAA purchased the drawings and data from Curtiss for £56,000, confirming the purchase with the British Purchasing Commission. The commission approved the resulting detailed design drawings, signing the commencement of the Mustang project on 4 May 1940, and firmly ordering 320 on 29 May 1940. Prior to this, NAA only had a letter of intent for an order of 320 aircraft. Curtiss engineers accused NAA of plagiarism. The British Purchasing Commission stipulated armament of four .303 in (7.7 mm) machine guns (as used on the Tomahawk), a unit cost of no more than $40,000, and delivery of the first production aircraft by January 1941. In March 1940, 320 aircraft were ordered by Freeman, who had become the executive head of the Ministry of Aircraft Production (MAP) and the contract was promulgated on 24 April. The NA-73X, which was designed by a team led by lead engineer Edgar Schmued, followed the best conventional practice of the era, designed for ease of mass manufacturing. The design included several new features. One was a wing designed using laminar flow airfoils, which were developed co-operatively by NAA and the National Advisory Committee for Aeronautics (NACA). These airfoils generated low drag at high speeds.
Sources: en.wikipedia.org
September 18 Russia and China veto a US proposal for UN experts to continue monitoring UN sanctions on Iran over its nuclear program. The US sentences a Syrian national who fraudulently immigrated to the country and served as the former head of the notorious Adra Prison under former Syrian president Bashar al-Assad to 60 years imprisonment on torture charges. Trump bans CNN, MS NOW, and Politico from the White House, accusing them of spreading "fake news." Greenland crisis: The United States, Denmark and Greenland announce an agreement to strengthen security in the Arctic and North Atlantic, expanding the permanent U.S. military presence in Greenland while recognising Danish sovereignty and Greenlandic self-determination. The agreement follows months of threats by President Trump to acquire or annex Greenland. September 19 The Trump administration approves a potential $2.68 billion sale of air defense equipment to Ukraine, adding that the country would finance it using a combination of European contributions and US foreign military financing. Trump signs the "Lindsey O Graham Sanctioning Russia and Iran Act of 2026," which allows him to impose tariffs of up to 100 percent on Russian oil buyers, including China and India, in response to the country's war in Ukraine, as well as to extend existing sanctions on Iran. The United States Southern Command states that its strike on a vessel in the Caribbean killed four people, adding that confirmed intelligence indicated the vessel’s active participation in narco-trafficking.
In March 2003, Cambridge Antibody Technology (CAT) stated its wish to "initiate discussions regarding the applicability of the royalty offset provisions for Humira" with Abbott Laboratories in the High Court of London. In November 2004, the trial began, and in December 2004, Justice Hugh Laddie ruled for CAT. A short version of the full statement of the proceedings was released. In it Justice Laddie remarked, "Abbott was in error when it made its first royalty payment to CAT calculated on the basis that only 2% of the Net Sales was due. It should have calculated on the basis of the full royalty of just over 5% and should have paid and continued to pay CAT accordingly." Justice Laddie went on to observe "...that the construction advanced by Abbott does violence to the language of the agreements, renders them obscure and makes little or no commercial sense. For this reason CAT wins the action." Abbott was required to pay CAT US$255 million, some of which was to be passed to its partners in development. Of this sum, the Medical Research Council received US$191 million, and in addition, Abbott was asked to pay the MRC a further US$7.5 million over five years from 2006, providing that Humira remains on the market. The MRC also is to receive a further £5.1 million (sterling) in respect of past royalties.
Epigenetics refers to the study of heritable changes in genetic activities that are distinct from changes in DNA sequences. Epigenetic analysis involves studying DNA-protein interactions, histone modifications, and DNA methylation. Linked-read sequencing has been used for studying DNA methylation patterns by many studies. For example, in 2021, a study investigated the DNA methylation differences in peripheral blood cells between twins, in which one twin had Alzheimer's Disease and the other was cognitively normal. Linked-read sequencing technology allowed researchers to identify more than 3000 differentially methylated regions between these twins discordant for Alzheimer's Disease, and investigation of these differentially methylated regions eventually led to identification of genes enriched in neurodevelopmental processes, neuronal signalling, and immune system functions
Lutetium's compounds almost always contain the element in the +3 oxidation state. Aqueous solutions of most lutetium salts are colorless and form white crystalline solids upon drying, with the common exception of the iodide, which is brown. The soluble salts, such as nitrate, sulfate and acetate form hydrates upon crystallization. The oxide, hydroxide, fluoride, carbonate, phosphate and oxalate are insoluble in water. Lutetium metal is slightly unstable in air at standard conditions, but it burns readily at 150 °C to form lutetium oxide. The resulting compound is known to absorb water and carbon dioxide, and it may be used to remove vapors of these compounds from closed atmospheres. Similar observations are made during reaction between lutetium and water (slow when cold and fast when hot); lutetium hydroxide is formed in the reaction. Lutetium metal is known to react with the four lightest halogens to form trihalides; except the fluoride they are soluble in water. Lutetium dissolves readily in weak acids and dilute sulfuric acid to form solutions containing the colorless lutetium ions, which are coordinated by between seven and nine water molecules, the average being [Lu(H2O)8.2]3+.
Sources: en.wikipedia.org
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.
Indirect evidence from animal studies supports central access, and the proposed mechanism requires it. Direct quantification in humans is limited. How much reaches specific brain regions remains an open question.
Published descriptions give a plasma half-life of roughly two to three hours after subcutaneous administration. Values vary with assay method and study population. The figure is an average rather than a fixed molecular property.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.